Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00655486 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
A Phase 3 study of Partial Epilepsies and Partial-onset Seizures, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 97
- Enrollment target
- 7
- Study locations
NCT00655486: Completed Phase 3 study of Partial Epilepsies and Partial-onset Seizures, sponsored by UCB Biosciences.
NCT00655486 is a Phase 3 study of Partial Epilepsies and Partial-onset Seizures that has completed, run by UCB Biosciences. The registered enrollment target is 97 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00655486, a Phase 3 study of Partial Epilepsies and Partial-onset Seizures, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 97 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to allow eligible subjects from the parent study, SP925 \[NCT00655551\] to continue lacosamide and to obtain additional long-term safety data
Primary Outcome
An Adverse Event (AE) is any untoward medical occurrence (eg, noxious or pathological changes) in a subject or clinical investigation subject compared with pre-existing conditions, that occurs during any period of a clinical trial including Pre-treatment, Run-In, Wash-Out, or Follow-Up Periods. An AE is defined as being independent of assumption of any causality (eg, to study or concomitant medication, primary or concomitant disease, or study design).
Conditions Studied
Interventions
- DRUG lacosamide
Study Locations (7)
Arizona
- - Phoenix
Maryland
- - Baltimore
Missouri
- - Chesterfield
Ohio
- - Columbus
Pennsylvania
- - Philadelphia
Texas
- - Dallas
Virginia
- - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
What the finished NCT00655486 record still lists
NCT00655486 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Partial Epilepsies appearing as the primary indexed condition, and to 1 intervention - of which lacosamide is the first listed.
NCT00655486 lists 7 locations in 7 states (Arizona, Maryland, Missouri).
Frequently Asked Questions
What is clinical trial NCT00655486 about?
NCT00655486 is a clinical study titled "Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures". The purpose of this study is to allow eligible subjects from the parent study, SP925 \[NCT00655551\] to continue lacosamide and to obtain additional long-term safety data
What is the current status of trial NCT00655486?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 97 participants. The study started on 2008-04. Estimated completion is 2010-06.
What conditions does trial NCT00655486 study?
This clinical trial studies the following conditions: Partial Epilepsies, Partial-onset Seizures.
What interventions are being tested in trial NCT00655486?
The interventions under investigation include: lacosamide (DRUG).
Who is sponsoring clinical trial NCT00655486?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00655486 being conducted?
This trial has 7 study locations across Arizona, Maryland, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Partial Epilepsies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00655486's enrollment target sits among peer trials
97 1718th of 2000 higher than 283 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia